Gene editing for common diseases faces safety and cost hurdles — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Gene editing therapies are being explored to replace lifelong medications for conditions like heart disease and diabetes, with early studies targeting sustained reductions in LDL cholesterol after a single treatment
- Eric D. Smith and Venkatesh L. Murthy propose five key questions to evaluate genomic therapies, including disease severity, existing treatment options, and long-term monitoring feasibility
- University of Michigan Health Frankel Cardiovascular Center researchers emphasize that unlike reversible medications, most gene therapies lack adjustable dosing or an 'off-switch,' increasing risks if side effects emerge
- Current gene therapies use modified viruses to deliver genetic changes to somatic cells, but immune responses may block re-administration if effects diminish over time
- Patient registries are cited as a model for long-term safety tracking, but scalable, standardized systems are needed if millions receive these treatments
- Some gene therapies have list prices exceeding $1 million, raising concerns that high costs could worsen healthcare disparities if applied to common conditions
Why it matters: If gene editing is adopted for widespread conditions, healthcare systems must balance unprecedented prevention potential against irreversible risks and million-dollar price tags. Without long-term safety data and equitable access plans, the technology could benefit few while straining infrastructure and deepening disparities.
Ask SkimNews
